Skip to content
eHealthTutorial — Research Peptide Reviews
Investigational • Not FDA-approved

Erythropoietin-derived research peptide

ARA 290 (Cibinetide)

ARA 290, also called cibinetide, is an engineered peptide derived from the structure of erythropoietin. Research has examined it in animal injury models and small clinical studies involving neuropathic symptoms and nerve-fiber measures.

Open calculator Explore the research
Generic research visual — not a commercial product
Compound typeEngineered erythropoietin-derived peptide
Evidence baseAnimal studies and exploratory human trials
Regulatory contextInvestigational / Not FDA-approved
Page purposeResearch and calculation

Compound calculator

ARA 290 (Cibinetide) reconstitution calculator

Enter the values printed on your vial and the liquid volume you added to calculate concentration, liquid volume, and the corresponding mark on a U-100 syringe scale.

Selected peptide or compoundARA 290 (Cibinetide)
Enter the total amount printed on the vial.
mL
Enter the liquid volume added in milliliters.
You provide this amount; the calculator does not select or recommend it.
Scale reference only; confirm the markings on the physical syringe.

Your ARA 290 (Cibinetide) calculation appears here

Enter the three required values to see the mathematical result.

This calculator performs arithmetic using values you enter. It does not select or recommend an amount, schedule, treatment, preparation method, or method of administration.

Research overview

What is ARA 290 (Cibinetide)?

ARA 290 is an 11-amino-acid peptide engineered from a surface region of erythropoietin. It is designed to engage a proposed innate-repair receptor pathway without reproducing erythropoietin’s red-blood-cell-stimulating activity. Cibinetide is a name used in later clinical research for this peptide. That design concept does not establish that every research product labeled ARA 290 matches a studied formulation.

What has researchers’ attention?

A small randomized pilot trial enrolled people with sarcoidosis and symptoms of small-fiber neuropathy. Its small-fiber symptom score improved relative to placebo, while some pain and fatigue measures improved in both groups rather than clearly separating treatment from placebo. A later randomized study of 64 participants assessed corneal nerve fiber area as a surrogate endpoint; one studied group showed a statistically significant increase versus placebo, while the other groups did not meet that threshold. Pain improved across groups, and the placebo-corrected pain comparison highlighted in a subgroup was not statistically significant. These are exploratory findings, not proof of a broadly effective or approved treatment.

Important limitation

The studies were limited in size, duration, populations, and endpoints. Changes in surrogate nerve-fiber measurements and selected symptom scores do not establish a treatment benefit, long-term safety, or appropriate use. No result validates the identity, sterility, or suitability of an affiliate supplier’s vial.

Research references

Calculation boundary

The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.